Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats

Transplantation

Volumn 62, Issue 7, 1996, Pages 986-994

  Stepkowski, Stanislaw M ^a   Napoli, Kimberly L ^a   Wang, Mou Er ^a   Qu, Xiumei ^a   Chou, Ting Chao ^b   Kahan, Barry D ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; RAPAMYCIN;

ADOLESCENT; ALLOGRAFT; ANIMAL TISSUE; ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG POTENTIATION; GRAFT REJECTION; GRAFT SURVIVAL; HEART GRAFT; IMMUNOSUPPRESSIVE TREATMENT; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CYCLOSPORINE; DRUG SYNERGISM; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNOSUPPRESSIVE AGENTS; MALE; POLYENES; RATS; RATS, INBRED WF; SIROLIMUS;

EID: 0029827815     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199610150-00018     Document Type: Article

References (45)

1. Verzina C, Kudelski A, Sehgal SN. Rapamycin (AY-22, 989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 1975; 28: 721.
2. Sehgal SN, Balor H, Verzina C. Rapamycin (AY 22, 989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo) 1975; 28: 727.
3. Baker H, Sidorowier A, Sehgal SN, Verzina C. Rapamycin (AY-22, 989), a new antifungal antibiotic. III. In vitro and in vivo evaluation. J Antibiot (Tokyo) 1978; 31: 539.
4. Findley YA, Radics L. On the chemistry and high field nuclear magnetic resonance spectroscopy of rapamycin. Can J Chem 1980; 58: 579.
5. Martel RR, Klicius Y, Galet S. Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol Pharmacol 1977; 55: 48.
6. Chang JY, Sehgal SN. Pharmacology of rapamycin: a new immunosuppressive agent. Br J Rheumatol 1991; 30 (suppl 20): 62.
7. Douros J, Suftness M. New antitumor substances of natural origin. Cancer Treat Rev 1981; 8: 63.
8. Calne RY, Collier DS, Lim S, et al. Rapamycin for immunosuppression in organ allografting [Letter]. Lancet 1989; 2: 227.
9. Morris RE, Meiser BM. Identification of a new pharmacologic action for an old compound [Letter]. Med Sci Res 1989; 17: 877.
10. Tu Y, Stepkowski SM, Chou T-C, Kahan BD. The synergistic effects of cyclosporine, sirolimus, and brequinar on heart allograft survival in mice. Transplantation 1995; 27: 177.
11. Morris RE, Wu J, Shorthouse R. A study of the contrasting effects of cyclosporine, FK506 and rapamycin on the suppression of allograft rejection. Transplant Proc 1990; 22: 1638.
12. Granger DK, Cromwell JW, Chen SC, et al. Prolongation of renal allograft survival in large animal model by oral rapamycin monotherapy. Transplantation 1995; 59: 183.
13. Stepkowski SM, Chen H, Daloze P, Kahan BD. Rapamycin, a potent immunosuppressive drug for vascularized heart, kidney and small bowel transplantation in the rat. Transplantation 1991; 51: 22.
14. Stepkowski SM, Chen H, Daloze P, Kahan BD. Prolongation by rapamycin of heart, kidney, pancreas, and small bowel allograft survival in rats. Transplant Proc 1991; 23: 507.
15. Stepkowski SM, Chen H, Wang M-E, Daloze P, Kahan BD. Inhibition of both host-versus-graft and graft versus-host responses after small bowel transplantation in rats by rapamycin. Transplantation 1992; 53: 258.
16. Kahan BD, Gibbons S, Tejpal N, Stepkowski SM, Chou T-C. Synergistic interactions of cyclosporine and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro. Transplantation 1991; 51: 232.
17. Martin DF, DeBarge LR, Nussenblatt RB, Chan C-C, Roberge FG. Synergistic effect of rapamycin and cyclosporine in the treatment of experimental autoimmune uveoretinitis. J Immunol 1995; 154: 922.
18. Liu J, Farmer JD, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991; 66: 804.
19. Clipstone NA, Crabtree GR. Calcineurin is a key signaling enzyme in T lymphocyte activation and the target of the immunosuppressive drugs cyclosporine A and FK506. Ann NY Acad Sci 1993; 696: 20.
20. Henderson DJ, Naya I, Bundick RV, Smith GM, Schmidt JA. Comparison of the effects of FK506, cyclosporine and rapamycin on IL-2 production. Immunology 1991; 73: 316.
21. Bierer BE, Mattila PS, Standaert RF, et al. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between immunophilin and either FK506 or rapamycin. Proc Natl Acad Sci USA 1990; 87: 9231.
22. Grevel J. Absorption of cyclosporine A after oral dosing. Transplant Proc 1986; 18: 9.
23. Hedayati S, Bernareggi A, Rowland M. Absorption kinetics of cyclosporin in the rat. J Pharm Pharmacol 1991; 43: 122.
24. Drewe J, Beglinger C, Kissel T. The absorption site of cyclosporin in the human gastrointestinal tract. Br J Clin Pharmacol 1992; 33: 39.
25. Vickers A, Fisher V, Connors S, et al. Cyclosporin A metabolism in human liver, kidney, and intestinal slices: comparison to rat and dog slices and human cell lines. Drug Metab Dispos 1992; 20: 802.
26. Neiderberger W, Lemaire M, Maurer G, Nussbaumer K, Wagner O. Distribution and binding of cyclosporine in blood and tissues. Transplant Proc 1983; 15 (suppl 1): 2419.
27. Maurer G. Metabolism of cyclosporine. Transplant Proc 1985; 17 (suppl 1): 19.
28. Wagner O, Schreier E, Heitz F, Maurer G. Tissue distribution, disposition, and metabolism of cyclosporine in rats. Drug Metab Dispos 1987; 15: 377.
29. Bernareggi A, Rowland M. Physiologic modeling of cyclosporin kinetics in rat and man. J Pharmacokinet Biopharm 1991; 19: 2.
30. Sangalli L, Bortolotti A, Jiritano L, Bonati M. Cyclosporine pharmacokinetics and interspecies comparison in dogs, rabbits, rats and humans. Drug Metab Dispos 1988; 16: 749.
31. Bachmann K, Sullivan T, Reese J, et al. The influence of dirithromycin on the rapamycin pharmacokinetics of cyclosporine in healthy subjects and in renal transplant patients. Am J Therapeutics 1995; 2: 490.
32. Dias V, Yatscoff R. Investigation of rapamycin transport and uptake across absorptive human intestinal cell monolayers. Clin Biochem 1994; 27: 31.
33. Honcharik N, Fryer J, Yatscoff R. Pharmacokinetics of rapamycin: single-dose studies in the rabbit. Ther Drug Monit 1992; 14: 475.
34. Supko J, Malspeis L. Dose-dependent pharmacokinetics of rapamycin-28-N,N-dimethylglycinate in the mouse. Cancer Chemother Pharmacol 1994; 33: 325.
35. Ono K, Lindsey ES. Improved technique of heart transplantation in rats. J Thorac Cardiovasc Surg 1969; 517: 225.
36. Napoli K, Kahan B. Sample clean-up and high-performance liquid chromatographic techniques for measurement of whole blood rapamycin concentrations. J Chromatogr 1994; 654: 111.
37. Abbott Diagnostics. TDX® immunosuppressant drug assay-cyclosporine monoclonal whole blood [Package insert]. Abbott Diagnostics, North Chicago, IL, 1993.
38. Chou T-C. The median-effect principle and the combination index for quantitation of synergism and antagonism. In: Chou TC, Rideout D, eds. Synergism and antagonism in chemotherapy. San Diego: Academic Press, 1991: 61.
39. Fryer J, Yatscoff R, Pascoe E, Thliveris J. The relationship of blood concentrations of rapamycin and cyclosporine to suppression of allograft rejection in the rabbit heterotopic heart transplant model. Transplantation 1993; 55: 340.
40. Yatscoff R, Wang P, Chan K, Hicks D, Zimmerman J. Rapamycin: distribution, pharmacokinetics, and therapeutic range investigations. Ther Drug Monit 1995; 17: 666.
41. Christians U, Sattler M, Schiebel H, et al. Isolation of two immunosuppressive metabolites after in vitro metabolism of rapamycin. Drug Metab Dispos 1992; 20: 186.
42. Hebert M, Roberts J, Prueksaritanont T, Benet L. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 1992; 52: 453.
43. Gomez D, Wacher V, Tomlanovich S, Hebert M, Benet L. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 1995; 58: 15.
44. Yee G. Pharmacokinetic interactions between cyclosporine and other drugs. Transplant Proc 1990; 22: 1203.
45. Kolars J, Schmiedin-Ren P, Schuetz J, Fang C, Watkins P. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992; 90: 1871.